A Phase 2/3 interventional study of MEDI8897 and Palivizumab in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 128 sites in 26 countries. Open to participants aged 0 Years to 1 Year. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by AstraZeneca · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 2/3, and was the 11th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 0 Years to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 2 started in 2019.
This study's enrollment of 925 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.
This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 900 palivizumab-eligible infants entering their first RSV season will be enrolled into one of 2 cohorts: (1) preterm cohort, including approximately 600 preterm infants (≤ 35 weeks gestational age [GA]) without CLD/CHD, or (2) CLD/CHD cohort, including approximately 300 infants with CLD of prematurity or hemodynamically significant CHD. A minimum of 100 infants with hemodynamically significant CHD will be enrolled. Within each cohort, randomization will be stratified by hemisphere (northern, southern) and subject age at the time of Season 1 randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born ≤ 35 weeks 0 days GA eligible to receive palivizumab in accordance with national or local guidelines, including those with:
For the CLD/CHD cohort:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
anti-RSV monoclonal antibody with an extended half-life
Drug: MEDI8897
anti-RSV monoclonal antibody
Drug: Palivizumab
Anti-RSV monoclonal antibody with an extended half-life
Approved anti-RSV monoclonal antibody
Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)
Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)
Time frame: 360 days post first dose
Serum Concentrations of MEDI8897 and Palivizumab
Summary of individual MEDI8897 and palivizumab serum concentration data by treatment group along with descriptive statistics.
Time frame: Day 15, Day 31, Day 151 post first dose in Season 1 and Season 2
Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum
Incidence of ADA to MEDI8897 and palivizumab as assessed by the percentage of participants with any post-baseline ADA positive by treatment group.
Time frame: 360 days post first dose
Incidence of Medically Attended Lower Respiratory Track Infection (LRTI) and Hospitalization Due to Reverse Transcriptase Chain Reaction (RT-PCR) Confirmed Respiratory Syncytial Virus (RSV) Through 150 Days Post First Dose
Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. Incidence of LRTI hospitalizations due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2.
Time frame: 150 days post first dose
In the overall population, 925 infants (615 in preterm cohort, 310 in CLD/CHD cohort) were enrolled from 25 countries and randomized (2:1) to MEDI8897 (n = 616) or palivizumab (n = 309). Of the 310 subjects in the Season 1 CLD/CHD cohort, 262 continued into the Season 2 phase of the study.
| Milestone | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Started | 616 | 309 | 0 | 0 | 0 |
| Completed | 543 | 263 | 0 | 0 | 0 |
| Not completed | 73 | 46 | 0 | 0 | 0 |
| Withdrew: Other | 6 | 7 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 43 | 28 | 0 | 0 | 0 |
| Withdrew: Due to covid-19 pandemic | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 17 | 7 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 1 | 0 | 0 | 0 |
| Milestone | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Started | 0 | 0 | 180 | 40 | 42 |
| Completed | 0 | 0 | 174 | 39 | 40 |
| Not completed | 0 | 0 | 6 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 |
Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)
| Participants | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| TEAE | 444 | 215 | 130 | 31 | 29 |
| TESAE | 80 | 38 | 23 | 4 | 2 |
| AESI | 3 | 0 | 1 | 0 | 0 |
| NOCD | 3 | 0 | 1 | 0 | 0 |
Summary of individual MEDI8897 and palivizumab serum concentration data by treatment group along with descriptive statistics.
| ug/mL | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Serum concentrations of MEDI8897 and Palivizumab at Day 15 | 104.75 ± 61.8 | 66.43 ± 55.7 | 149.38 ± 169.2 | 97.70 ± 302.0 | 59.62 ± 102.4 |
| Serum concentrations of MEDI8897 and Palivizumab at Day 31 | 85.35 ± 74.2 | 48.10 ± 50.0 | 89.71 ± 369.5 | 124.89 ± 256.1 | 57.77 ± 56.3 |
| Serum concentrations of MEDI8897 and Palivizumab at Day 151 | 25.38 ± 58.8 | 101.56 ± 65.6 | 39.86 ± 145.9 | 37.95 ± 118.6 | 67.66 ± 111.4 |
Incidence of ADA to MEDI8897 and palivizumab as assessed by the percentage of participants with any post-baseline ADA positive by treatment group.
| Percentage of participants | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum | 5.8 | 6.9 | 11.7 | 2.5 | 14.3 |
Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. Incidence of LRTI hospitalizations due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2.
| Percentage of participants | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Incidence of medically attended RSV LRTI through 150 days post first dose, % | 0.6 | 1.0 | 0 | 0 | 0 |
| Incidence of medically attended RSV LRTI with hospitalization through 150 days post first dose, % | 0.3 | 0.6 | 0 | 0 | 0 |
Collected over Through 360 days post first dose of Season 1 for MEDI8897 and Palivizumab groups, through 360 days post first dose of Season 2 for MEDI8897/MEDI8897, MEDI8897/Palivizumab, and Palivizumab/Palivizumab groups.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEDI8897 | 5/614 (0.8%) | 80/614 (13%) | 435/614 (70.8%) |
| Palivizumab | 1/304 (0.3%) | 38/304 (12.5%) | 211/304 (69.4%) |
| MEDI8897/MEDI8897 | 0/180 (0%) | 23/180 (12.8%) | 129/180 (71.7%) |
| Palivizumab/MEDI8897 | 0/40 (0%) | 4/40 (10%) | 31/40 (77.5%) |
| Palivizumab/Palivizumab | 0/42 (0%) | 2/42 (4.8%) | 29/42 (69%) |
| Event | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 5/614 | 1/304 | 2/180 | 2/40 | 0/42 |
| Bone abscessInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| Ear infectionInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| GastroenteritisInfections and infestations | 6/614 | 1/304 | 3/180 | 1/40 | 1/42 |
| Gastrointestinal infectionInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| Lower respiratory tract infectionInfections and infestations | 1/614 | 2/304 | 2/180 | 1/40 | 0/42 |
| MastoiditisInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| Otitis mediaInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| Otitis media acuteInfections and infestations | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| NystagmusNervous system disorders | 0/614 | 0/304 | 0/180 | 1/40 | 0/42 |
| Event | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 148/614 | 77/304 | 48/180 | 8/40 | 9/42 |
| PyrexiaGeneral disorders | 81/614 | 43/304 | 23/180 | 9/40 | 6/42 |
| NasopharyngitisInfections and infestations | 57/614 | 39/304 | 26/180 | 7/40 | 9/42 |
| Viral upper respiratory tract infectionInfections and infestations | 33/614 | 14/304 | 14/180 | 8/40 | 2/42 |
| DiarrhoeaGastrointestinal disorders | 29/614 | 11/304 | 10/180 | 2/40 | 7/42 |
| RhinitisInfections and infestations | 75/614 | 40/304 | 29/180 | 6/40 | 6/42 |
| Otitis media acuteInfections and infestations | 16/614 | 14/304 | 11/180 | 5/40 | 2/42 |
| Covid-19Infections and infestations | 8/614 | 2/304 | 14/180 | 3/40 | 5/42 |
| VomitingGastrointestinal disorders | 15/614 | 11/304 | 6/180 | 4/40 | 3/42 |
| BronchitisInfections and infestations | 20/614 | 10/304 | 7/180 | 4/40 | 1/42 |
| Age, Continuous(Months) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Age at randomization (months) | 3.947 ± 2.5513 | 3.840 ± 2.4608 | — | — | — | 3.911 ± 2.5206 |
| Age, Continuous(Months) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Age at first dose of Season 2 (Months) | — | — | 16.772 ± 2.7141 | 16.598 ± 2.4335 | 16.132 ± 2.1040 | 16.643 ± 2.5857 |
| Sex: Female, Male(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Female | 297 | 133 | 0 | 0 | 0 | 430 |
| Male | 319 | 176 | 0 | 0 | 0 | 495 |
| Sex: Female, Male(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 81 | 15 | 15 | 111 |
| Male | 0 | 0 | 99 | 25 | 27 | 151 |
| Race (NIH/OMB)(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 11 | 5 | 0 | 0 | 0 | 16 |
| Asian | 36 | 14 | 0 | 0 | 0 | 50 |
| Native Hawaiian or Other Pacific Islander | 4 | 1 | 0 | 0 | 0 | 5 |
| Black or African American | 59 | 29 | 0 | 0 | 0 | 88 |
| White | 483 | 249 | 0 | 0 | 0 | 732 |
| More than one race | 6 | 4 | 0 | 0 | 0 | 10 |
| Unknown or Not Reported | 17 | 7 | 0 | 0 | 0 | 24 |
| Race (NIH/OMB)(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 10 | 3 | 2 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 9 | 2 | 1 | 12 |
| White | 0 | 0 | 152 | 35 | 38 | 225 |
| More than one race | 0 | 0 | 3 | 0 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 5 | 0 | 0 | 5 |
| Congenital heart disease(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Yes | 70 | 34 | 0 | 0 | 0 | 104 |
| No | 546 | 275 | 0 | 0 | 0 | 821 |
| Congenital heart disease(Participants) | MEDI8897 | Palivizumab | MEDI8897/MEDI8897 | Palivizumab/MEDI8897 | Palivizumab/Palivizumab | Total |
|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 56 | 14 | 11 | 81 |
| No | 0 | 0 | 124 | 26 | 31 | 181 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 128 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2019 to primary completion in May 2021, 21 months.
Results were first posted in Sep 2023, 2 years 4 months after primary completion. A results delay was requested in Feb 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →